FREMONT, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Vermillion, Inc. today announced the reappointment of Gail S. Page as Chief Executive Officer of the Company and Eric T. Fung, MD, PhD as Senior Vice President and Chief Science Officer of the Company. In addition, the previously announced appointment of William C. Wallen, PhD to the Board of Directors is now effective. Ms. Page will continue to act as Chair of the Board of Directors.
Ms. Page joined the company in 2004 as President to lead the formation of the Diagnostics division. From December 2005 to March 2009, she served as President and Chief Executive Officer. On March 27, 2009, Ms. Page was appointed Executive Chair and was responsible for leading Vermillion through the successful reorganization and exit from Chapter 11. Ms. Page has been a member of the Board of Directors since 2006.
Dr. William Wallen was appointed to the Board of Directors on December 10, 2009. He is currently the Chief Scientific Officer, Senior Vice President for Research and Development for IDEXX Laboratories and previously served on Vermillion's Scientific Advisory Board.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at www.vermillion.com.
The OVA1(TM) Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
Forward-Looking Statement
CONTACT: Jill Totenberg, +1-212-994-7363, jt@totenberggroup.com
Web site: http://www.vermillion.com/
